Instrument Inactif

Autres langues Discovery Laboratories, Inc. Nasdaq

Actions

US2546684034

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

19/03	Evofem Biosciences, Inc. annonce la résiliation de son accord de licence et d'approvisionnement avec Windtree Therapeutics, Inc. sans pénalités	CI
07/01	Windtree Therapeutics, Inc. annonce la démission d'Eric L. Curtis de ses fonctions de président et directeur des opérations, à compter du 5 janvier 2026	CI

Autres langues

19/03	Evofem Biosciences, Inc. Announces Termination of License and Supply Agreement with No Fees Payable with Windtree Therapeutics, Inc
07/01	Windtree Therapeutics, Inc. Announces Resignation of Eric L. Curtis as President and Chief Operating Officer, Effective January 5, 2026
23/12	Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates
23/12	Windtree Therapeutics, Inc. Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates
03/12	Windtree Therapeutics announces it has signed a letter of intent to acquire CommLoan
03/12	Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space
02/12	Windtree Therapeutics, Inc. signed a letter of intent to acquire CommLoan, Inc. in a reverse merger transaction.
25/11	Windtree Therapeutics, Inc. announced that it has received $0.6 million in funding
19/11	Windtree Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
17/11	Windtree Therapeutics, Inc. Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee
17/11	Windtree Therapeutics announces it may receive license agreement payments from its licensee for renewed acute pulmonary development by the licensee
17/11	Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee
17/11	Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate
14/11	Windtree Therapeutics Announces More Strengthening of Its Istaroxime and Next Generation SERCA2a activator Patent Estate
13/11	Windtree Therapeutics Announces It Will Receive $7.5 Million In Cash and Securities from the Recently Executed Termination Agreement with an Environmental Services Company
13/11	Windtree Therapeutics, Inc. cancelled the acquisition of Titan Environmental Services, Inc..
09/10/25	Windtree Therapeutics, Inc. announced that it has received $1.6 million in funding
08/09/25	Windtree Therapeutics, Inc. Announces Resignation of Steven G. Simonson as Senior Vice President and Chief Medical Officer Effective, September 2, 2025
02/09/25	Windtree Therapeutics stockholders approve key proposals for revenue and profit generation at the special stockholder meeting
02/09/25	Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting
25/08/25	Windtree Therapeutics, Inc.(OTCPK:WINT) dropped from S&P TMI Index
20/08/25	Windtree Therapeutics, Inc.(OTCPK:WINT) dropped from NASDAQ Composite Index
19/08/25	Windtree Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
11/08/25	Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
09/08/25	Windtree Therapeutics terminates Seismic-C clinical study at 20 enrollments - SEC filing